Drug Profile
Research programme: glycodesigned biotherapeutics - Glycotope
Alternative Names: GatoMab-GEX; GT-MAB 3.2-GEX; SeeloMab-GEXLatest Information Update: 28 Mar 2018
Price :
$50
*
At a glance
- Originator GLYCOTOPE
- Developer Glycotope
- Class Biobetters; Drug conjugates; Immunoconjugates; Monoclonal antibodies; Proteins
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Mar 2018 No recent reports of development identified for preclinical development in Cancer in Germany (Parenteral)
- 24 Jul 2017 SeeloMab-GEX™ is available for licensing as of 24 Jul 2017. http://www.glycotope.com/biopharmaceuticals-pipeline/ (Glycotope pipeline, July 2017)
- 23 Mar 2016 Preclinical development is ongoing for cancer in Germany